Literature DB >> 22718277

Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid β neurotoxicity in vitro.

Xianwu Li1, Shannon E Rose, Kathleen S Montine, C Dirk Keene, Thomas J Montine.   

Abstract

Multiple lines of evidence indicate that regional brain eicosanoid signaling is important in initiation and progression of neurodegenerative conditions that have neuroinflammatory pathologic component, such as AD. We hypothesized that PGE(2) receptor subtype 1 (EP1) signaling (linked to intracellular Ca(2+) release) regulates Aβ peptide neurotoxicity and tested this in two complementary in vitro models: a human neuroblastoma cell line (MC65) producing Aβ(1-40) through conditional expression of the APP C-terminal portion, and murine primary cortical neuron cultures exposed to Aβ(1-42). In MC65 cells, EP1 receptor antagonist SC-51089 reduced Aβ neurotoxicity ~50 % without altering high molecular weight Aβ immunoreactive species formation. Inositol-3-phosphate receptor antagonist 2-aminoethoxy-diphenyl borate offered similar protection. SC-51089 largely protected the neuron cultures from synthetic Aβ(1-42) neurotoxicity. Nimodipine, a Ca(2+) channel blocker, was completely neuroprotective in both models. Based on these data, we conclude that suppressing neuronal EP1 signaling may represent a promising therapeutic approach to ameliorate Aβ peptide neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718277      PMCID: PMC3700810          DOI: 10.1007/s11481-012-9380-1

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  40 in total

1.  PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease.

Authors:  Gehua Zhen; Yun Tai Kim; Rung-chi Li; Jennifer Yocum; Nidhi Kapoor; John Langer; Peter Dobrowolski; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurobiol Aging       Date:  2011-10-19       Impact factor: 4.673

2.  Suppressed microglial E prostanoid receptor 1 signaling selectively reduces tumor necrosis factor alpha and interleukin 6 secretion from toll-like receptor 3 activation.

Authors:  Xianwu Li; Eiron Cudaback; C Dirk Keene; Richard M Breyer; Thomas J Montine
Journal:  Glia       Date:  2011-01-06       Impact factor: 7.452

3.  Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

Authors:  G P Lim; F Yang; T Chu; P Chen; W Beech; B Teter; T Tran; O Ubeda; K H Ashe; S A Frautschy; G M Cole
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

4.  Elevated CSF prostaglandin E2 levels in patients with probable AD.

Authors:  T J Montine; K R Sidell; B C Crews; W R Markesbery; L J Marnett; L J Roberts; J D Morrow
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

5.  Prostaglandin E2 reduces amyloid beta-induced phagocytosis in cultured rat microglia.

Authors:  Takayuki Nagano; Shinya H Kimura; Motohiko Takemura
Journal:  Brain Res       Date:  2010-02-06       Impact factor: 3.252

6.  Cyclooxygenase (COX)-1 activity precedes the COX-2 induction in Aβ-induced neuroinflammation.

Authors:  Leila Dargahi; Shiva Nasiraei-Moghadam; Azadeh Abdi; Leila Khalaj; Fatemeh Moradi; Abolhassan Ahmadiani
Journal:  J Mol Neurosci       Date:  2010-06-12       Impact factor: 3.444

Review 7.  Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease.

Authors:  C Dirk Keene; Eiron Cudaback; Xianwu Li; Kathleen S Montine; Thomas J Montine
Journal:  Curr Opin Neurobiol       Date:  2011-09-08       Impact factor: 6.627

8.  Amyloid-β induces cyclooxygenase-2 and PGE2 release in human astrocytes in NF-κ B dependent manner.

Authors:  Almudena Blanco; Susana Alvarez; Manuel Fresno; Maria Ángeles Muñoz-Fernández
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

9.  Decreased clearance of CNS beta-amyloid in Alzheimer's disease.

Authors:  Kwasi G Mawuenyega; Wendy Sigurdson; Vitaliy Ovod; Ling Munsell; Tom Kasten; John C Morris; Kevin E Yarasheski; Randall J Bateman
Journal:  Science       Date:  2010-12-09       Impact factor: 47.728

10.  Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.

Authors:  Thomas J Montine; Joshua A Sonnen; Ginger Milne; Laura D Baker; John C S Breitner
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

View more
  11 in total

1.  Prostaglandin EP2 Receptors Mediate Mesenchymal Stromal Cell-Neuroprotective Effects on Dopaminergic Neurons.

Authors:  Juan Andrés Parga; María García-Garrote; Salvador Martínez; Ángel Raya; José Luis Labandeira-García; Jannette Rodríguez-Pallares
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

2.  Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer's disease.

Authors:  Erica J Melief; Eiron Cudaback; Nikolas L Jorstad; Emily Sherfield; Nadia Postupna; Angela Wilson; Martin Darvas; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  J Neurosci Res       Date:  2015-03-30       Impact factor: 4.164

3.  Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia.

Authors:  Xianwu Li; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  FASEB J       Date:  2015-01-15       Impact factor: 5.191

4.  Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease.

Authors:  Yue Yang; C Dirk Keene; Elaine R Peskind; Douglas R Galasko; Shu-Ching Hu; Eiron Cudaback; Angela M Wilson; Ge Li; Chang-En Yu; Kathleen S Montine; Jing Zhang; Geoffrey S Baird; Bradley T Hyman; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2015-07       Impact factor: 3.685

Review 5.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

6.  Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.

Authors:  Marta Anglada-Huguet; Xavier Xifró; Albert Giralt; Alfonsa Zamora-Moratalla; Eduardo D Martín; Jordi Alberch
Journal:  Mol Neurobiol       Date:  2013-11-07       Impact factor: 5.590

7.  Microglial-neuronal interactions during neurodegenerative diseases.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2013-02-13       Impact factor: 4.147

8.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

9.  Characterization of cognitive impairments and neurotransmitter changes in a novel transgenic mouse lacking Slc10a4.

Authors:  E J Melief; J T Gibbs; X Li; R G Morgan; C D Keene; T J Montine; R D Palmiter; M Darvas
Journal:  Neuroscience       Date:  2016-03-19       Impact factor: 3.590

10.  Hippocampal neuronal cyclooxygenase-2 downstream signaling imbalance in a rat model of chronic aluminium gluconate administration.

Authors:  Hong Wang; Mengliang Ye; Lijuan Yu; Jianfeng Wang; Yuanxin Guo; Wenjuan Lei; Junqing Yang
Journal:  Behav Brain Funct       Date:  2015-02-18       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.